ICC award looms in US-Chinese biotech dispute
I-Mab and Tracon collaborated to develop cancer-fighting drugs (Credit: Shutterstock/H_Ko)
A US biotech company and its Chinese partner are awaiting an ICC award in a US$200 million-plus dispute over a collaboration to develop cancer-fighting antibodies.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now